Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
63 studies found for:    cladribine
Show Display Options
Rank Status Study
1 Recruiting Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Cladribine;   Procedure: Stem Cell Transplant;   Drug: G-CSF;   Drug: Methotrexate
2 Recruiting Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Behavioral: Phone Calls
3 Recruiting Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Cytarabine;   Drug: Decitabine
4 Recruiting 2CDA With Rituximab in Hairy Cell Leukemia
Condition: Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
5 Completed 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Condition: Leukemia
Interventions: Drug: 2-CdA;   Drug: Ara-C;   Drug: G-CSF (Granulocyte colony-stimulating factor)
6 Active, not recruiting Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Condition: Lymphoma
Interventions: Drug: 2CdA;   Drug: Cyclophosphamide;   Drug: Rituximab
7 Suspended Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Cladribine;   Drug: Rituximab
8 Recruiting Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: filgrastim;   Drug: mitoxantrone hydrochloride;   Drug: cladribine;   Drug: cytarabine
9 Recruiting Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Condition: Multiple Sclerosis
Intervention: Drug: Cladribine
10 Recruiting R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
11 Completed Study Assessing the Interaction of Pantoprazole With Cladribine in Subjects With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Cladribine and Pantoprazole
12 Recruiting Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: bortezomib;   Drug: Cladribine
13 Recruiting Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Intervention: Drug: Cladribine s.c. injection, HCL treatment
14 Recruiting 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
Condition: Leukemia
Interventions: Drug: SGI-110;   Drug: Idarubicin;   Drug: Cladribine
15 Completed
Has Results
Oral Cladribine in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Cladribine;   Drug: Placebo;   Drug: Rebif® new formulation (RNF)
16 Active, not recruiting Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: rituximab;   Drug: cladribine;   Drug: vorinostat;   Other: laboratory biomarker analysis
17 Recruiting Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis
Condition: Langerhans Cell Histiocytosis of Lung
Intervention: Drug: Cladribine
18 Completed
Has Results
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine 5.25 mg/kg;   Drug: Cladribine 3.5 mg/kg;   Other: Placebo
19 Completed Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Cladribine;   Drug: Cytarabine;   Drug: All-Trans Retinoic Acid (ATRA);   Drug: Midostaurin
20 Unknown  Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
Condition: Leukemia, Myelocytic, Acute
Intervention: Drug: cladribine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years